Co-Inventors
Coble, Vincent
Ishizuka, Andrew
Zhu, Yaling
Therapeutic Areas
Oncology
Infectious Disease
Immunology
Research Products
Research Equipment
Animal Models
This technology presents innovative methods for manufacturing peptide-based vaccines that effectively induce T cell responses. By linking peptide antigens to adjuvants with hydrophobic blocks, a conjugate vaccine is created that self-assembles into nanoparticles, also known as immunotherapeutic nanoscaffolds (IMNs). These methods, which improve the efficiency and reduce the costs of peptide vaccine production, include constructing the conjugate entirely on resin to reduce reaction steps, producing a product solution with an excess of unreacted hydrophobic block to minimize purification steps, enhancing formulation stability by mixing several conjugates, and providing a simple sterilization process through sterile filtering and reconstitution in aqueous solution.
Commercial Applications
The potential applications of this technology are broad, spanning various fields including personalized medicine, infectious disease prevention, and cancer immunotherapy. The ability to efficiently manufacture peptide-based vaccines that induce T cell responses opens doors for personalized therapies tailored to individual patients. In infectious disease prevention, these vaccines could be used to target specific pathogens, offering a more precise and effective approach compared to traditional vaccines. Additionally, in cancer immunotherapy, peptide-based vaccines have shown promise in stimulating immune responses against tumor cells. The technology's scalability and efficiency also make it suitable for large-scale vaccine production, addressing global health challenges such as pandemics. Overall, the technology has the potential to revolutionize vaccine development and personalized medicine, impacting healthcare on a global scale.
Competitive Advantages
This novel technology offers several competitive advantages over existing methods for manufacturing peptide-based vaccines. By streamlining the process to construct the conjugate entirely on resin, it reduces reaction steps and minimizes the complexity of purification processes, leading to cost savings and increased efficiency. The ability to produce a product solution with an excess of unreacted hydrophobic block further simplifies purification, enhancing scalability and reducing manufacturing time. Additionally, the improved formulation stability achieved by mixing several conjugates provides a more robust vaccine product. Lastly, the facile sterilization process, involving sterile filtering and reconstitution in aqueous solution, adds to the technology's appeal by simplifying the final manufacturing steps. These advantages position the technology as a promising solution for the efficient and cost-effective production of peptide-based vaccines with enhanced stability and scalability.
